higher concentrations of aldosterone metabolites in the plasma of these patients. The effect of this is that a commonly used automated aldosterone immunoassay overestimates plasma aldosterone in renal impairment, and the magnitude of this bias increases with the worsening of renal function. In comparison to results for individuals with normal renal function, the assay overestimates aldosterone on average by 129% in hemodialysis patients and 42% in moderate renal failure [eGFR 30 -60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 ] and 27% in patients with mild renal impairment [eGFR 60 -90 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 ]. Overestimation of aldosterone in patients on dialysis and in endstage renal failure is not widely recognized although it has been reported previously (1) (2) (3) . Our study is the first to demonstrate that this problem extends to mild and moderate renal impairment. Although large differences between immunoassays for aldosterone have previously been described (4 ), it is likely that direct immunoassays for plasma aldosterone other than the one we used would also be subject to interference from aldosterone metabolites in patients with renal impairment.
The screening and diagnosis of diseases such as primary aldosteronism depend on the accuracy of aldosterone measurements. Up to one-fifth of patients with newly diagnosed primary aldosteronism may have significant renal impairment (5 ) and the assay overestimation we describe may increase the likelihood of incorrect diagnosis at both the screening and confirmatory stages of investigation of such patients. We note, however, that the clinical outcomes reported in the existing literature are primarily based on aldosterone immunoassays. Although we have not confirmed this finding, the requirement of solvent extraction in mass spectrometry would eliminate the overestimation observed. Indeed, aldosterone is not overestimated by mass spectrometry in patients on hemodialysis (2 ). Our results indicate that caution is needed in the interpretation of plasma aldosterone measurements by immunoassay in patients with renal impairment, and, when accurate measurements are required, a liquid extraction step or mass spectrometry should be considered. 
Smartphones Can Monitor Medical Center Pneumatic Tube Systems

To the Editor:
The pneumatic tube system (PTS) has become a common means of transportation of specimens in medical centers. Although the PTS provides convenience and speed of transport, hemolysis of blood specimens and preanalytical variation have been related to excessive acceleration forces and prolonged time/ distance traveled in the PTS (1) (2) (3) (4) (5) . As a result, regular assessment of 3-axis acceleration (i.e., forces) in PTSs has been recommended in an article in this journal (5 ) . An editorial related to that article suggested that products designed for PTS assessment may become commercially available and capable of recording g-forces in PTSs (2 ). To date, however, we have found no products that are available in the US designed to record forces in the PTS used in our health system (Swisslog).
Many modern smartphones are equipped with an accelerometer that measures acceleration forces. The devices also contain a chronometer, and they are nearly ubiquitous and are portable, and small enough to fit in a PTS carrier, suggesting that they might be useful for monitoring forces and time associated with travel of samples through a PTS.
To explore this possibility, we used a relatively old cell phone (iPhone 5) and a readily available data logger app (Sensor Kinetics Pro). The smartphone was wrapped in bubble wrap, placed in a carrier, and sent through the hospital PTS. The data logger app collected data on 3-axis acceleration vs time in transit. As shown in Fig. 1 , the smartphone experienced shocks with peak acceleration forces exceeding 8g (78 m/s 2 ). These forces are similar to the forces of up to 10g reported by Streichert et al. in their PTS when it was at a high-speed setting (5 ). Streichert et al. documented that such forces are associated with sample hemolysis. The smartphones that we sent through the PTS were not damaged during transport, and the results were reproducible when the smartphone was sent through the PTS repeatedly (not shown).
The iPhones, like most smartphones, also have audiovisual recording capabilities and a light source. We used these capabilities to visualize the effect of acceleration forces on blood samples during transit through the PTS. One smartphone was used to make an audiovisual recording of blood in a filled heparinized sample tube, and a second smartphone illuminated the tube in the carrier. As can be seen in the resulting smartphone video (see the online Supplemental Video link that accompanies the online version of this article at http:// www.clinchem.org/content/vol62/ issue6), the sample experienced marked turbulence, resulting in a foamy or frothy appearance of the blood sample, with large and small air pockets. The foamy appearance of the sample was readily appreciated upon direct visual inspection immediately after transport of the sample, but dissipated within a few minutes.
These findings suggest that smartphones can be used to quickly and economically monitor the PTS variables of force and time that have been shown to affect the integrity of patient specimens. Although we used an iPhone 5, other types of smartphones have similar capabilities and presumably could be used; this possibility will require documentation. Due to the convenience and efficiency of this approach, it has several possible applications in medical centers that use PTSs: (a) a medical center may use this approach to establish PTS acceptability criteria or recommend thresholds not to be exceeded to ensure sample integrity during transport; (b) this approach can be used to investigate a presumptive problematic PTS route; (c) because PTS routes are often installed, and may be modified during medical center renovations, this approach can be used to quickly assess or reassess route performance and consistency; and (d) this approach may be especially useful for more-frequent monitoring of PTS routes that service specific patient populations (such as oncology or hematology patients) whose blood samples may be more susceptible to cellular damage during transport.
Smartphones appear to provide the capabilities needed to monitor medical center PTSs, with the benefits of being cost effective, convenient, and widely available. Letters to the Editor
